Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report released on Sunday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Up 1.7 %

Shares of SENS opened at $0.31 on Friday. The stock’s 50-day moving average price is $0.34 and its two-hundred day moving average price is $0.39. Senseonics has a 12 month low of $0.28 and a 12 month high of $0.75. The company has a market capitalization of $183.72 million, a PE ratio of -2.32 and a beta of 0.79. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17.

Hedge Funds Weigh In On Senseonics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System acquired a new position in Senseonics in the first quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the period. Vanguard Group Inc. boosted its stake in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after acquiring an additional 155,715 shares in the last quarter. Virtu Financial LLC acquired a new stake in Senseonics in the first quarter worth $162,000. Finally, GSA Capital Partners LLP bought a new stake in Senseonics in the third quarter valued at $117,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.